sprite-preloader
Sonntag, 30.04.2017 Börsentäglich über 12.000 News von 563 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

Aktuelle News von Pharmaceutical Business Review

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
FrTakeda, Harrington to advance development of rare disease therapeutics
FrFDA grants Pfizer's Lorlatinib breakthrough designation for NSCLC
FrAstraZeneca elects to return AZD9412 drug rights to Synairgen
DoShire wins EC conditional approval for Natpar to treat hypoparathyroidism
DoTeva launches generic Vytorin tablets in US
DoGates Foundation leads $45.5m round for biotechnology firm Arsanis
MiAkebia expands anemia drug collaboration with Otsuka
MiuniQure's gene therapy for severe hemophilia B gets PRIME designation in Europe
MiClinical trial technology firm Science 37 raises $29m funding
MiEC approves AstraZeneca's Tagrisso to treat mutation-positive NSCLC
DiPfizer's Zavicefta matches standard-of-care in treating hospital-acquired pneumonia in phase 3 study
DiEMA's CHMP recommends approval for Kevzara for rheumatoid arthritis
DiFresenius Kabi agrees to acquire Akorn for $4.3bn
MoLack of demand forces uniQure to withdraw Glybera gene therapy in Europe
MoNGM Bio's NGM282 succeeds in nonalcoholic steatohepatitis phase 2 trial
MoBiosimilars to rituximab, etanercept recommended for approval in Europe
MoFDA rejects Vernalis' NDA for cough cold treatment
21.04.AbbVie's pan-genotypic HCV regimen achieves 99% cure rate in phase 3 study
21.04.H3 Biomedicine, Foundation Medicine extend precision oncology collaboration
21.04.Immune Pharmaceuticals licenses cancer treatment's Latin America rights to Pint
21.04.Sawai to buy Upsher-Smith's generic pharmaceuticals business for $1.05bn
20.04.Novartis signs collaboration deal with Parvus for diabetes nanomedicine
20.04.Ultragenyx's hypophosphatemia drug succeeds in phase 3 study
20.04.Alpine Immune Sciences to merge with Nivalis Therapeutics
20.04.Relypsa's Veltassa shows consistent efficacy in phase 4 trial to treat hyperkalemia